PUBLISHER: The Business Research Company | PRODUCT CODE: 1948214
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948214
Small volume parenteral (SVP) relates to a classification of sterile pharmaceuticals designed for parenteral delivery (circumventing the gastrointestinal tract) and usually dispensed in volumes of 100 milliliters (mL) or smaller. These items serve diverse medical functions, such as administering medications, vaccines, or biological therapies directly into the body via intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes.
The primary categories of small volume parenteral include ampules, vials, and prefilled syringes. Ampules are compact, sealed containers utilized for storing and protecting liquid medications, typically opened by breaking off the neck. Available in single or multiple doses, they are employed to address diverse conditions such as pain management, cancer treatment, malnutrition, gastrointestinal issues, diabetes, among others. Widely used in local anesthetics, vaccines, and similar applications, they cater to various end users including hospitals, clinics, ambulatory surgical centers, and others.
Tariffs are impacting the small volume parenteral market by increasing costs of imported glass vials, ampules, elastomeric closures, sterile filling equipment, and pharmaceutical-grade raw materials. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported packaging and processing equipment, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are raising manufacturing costs and influencing drug pricing strategies. However, they are also encouraging domestic vial manufacturing, local aseptic filling capacity expansion, and investments in advanced injectable drug production infrastructure.
The small volume parenteral market research report is one of a series of new reports from The Business Research Company that provides small volume parenteral market statistics, including small volume parenteral industry global market size, regional shares, competitors with a small volume parenteral market share, detailed small volume parenteral market segments, market trends and opportunities, and any further data you may need to thrive in the small volume parenteral industry. This small volume parenteral market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The small volume parenteral market size has grown strongly in recent years. It will grow from $191.36 billion in 2025 to $207.18 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing use of injectable therapies, expansion of hospital-based drug administration, availability of glass ampule packaging, growth of acute care treatments, rising demand for parenteral nutrition.
The small volume parenteral market size is expected to see strong growth in the next few years. It will grow to $275.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing demand for biologics and vaccines, rising adoption of self-injectable therapies, expansion of aseptic manufacturing capacity, growing focus on advanced drug delivery systems, increasing investments in sterile packaging technologies. Major trends in the forecast period include increasing adoption of prefilled syringe formats, rising demand for sterile injectable drugs, growing use of single-dose parenterals, expansion of vaccine and biologic administration, enhanced focus on drug safety and stability.
The increasing number of surgeries is expected to drive the growth of the small-volume parenteral market going forward. Surgery is a medical specialty that involves operative techniques to investigate or treat pathological conditions, improve bodily function or appearance, or repair damaged areas. The rising rate of surgeries, fueled by advancements in medical technology and an aging population, is increasing demand for surgical interventions. Small-volume parenteral solutions are used in surgeries to deliver medications, electrolytes, and nutrients directly into the bloodstream with precision. For instance, in June 2024, according to the American Society of Plastic Surgeons, a US-based non-profit organization, minimally invasive procedures increased by 7% in 2023, exceeding the overall growth rate of surgical procedures by 2%. Hand surgeries such as carpal tunnel, arthritis, and trigger finger totaled 207,887 procedures, marking a 2% increase from 2022. Therefore, the rising number of surgeries is propelling the growth of the small-volume parenteral market.
Major companies in the small-volume parenteral market are increasingly developing prefilled, ready-to-use injectable formulations to improve dosing precision, minimize contamination risk, and enhance patient safety. Prefilled, ready-to-use injectables are medications supplied in a sterile syringe or vial, allowing direct administration without additional preparation. For instance, in June 2025, Gland Pharma Limited, an India-based pharmaceutical company specializing in generic injectables, received USFDA approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL. This injection is indicated for rapidly raising blood pressure in adults with septic or distributive shock when standard therapies are insufficient. It works by binding to vascular smooth muscle receptors, causing vasoconstriction and stimulating aldosterone release, with a rapid onset that typically achieves target blood pressure within five minutes. Administered intravenously, the dosage is carefully titrated to maintain desired blood pressure, providing critical support to patients who remain hypotensive despite fluid resuscitation and vasopressor therapy.
In February 2024, Eris Lifesciences Ltd., a pharmaceutical firm headquartered in India, acquired a majority stake of 51% in Swiss Parenteral for $76.52 million. This strategic move by Eris enhances its footprint in the sterile injectables sector and aligns with its strategy of targeting emerging markets. Swiss Parenteral, also based in India, specializes in the production of small-volume liquid parenteral formulations within the pharmaceutical industry.
Major companies operating in the small volume parenteral market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Viatris Inc, Intas Pharmaceuticals Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Alembic Pharmaceuticals Ltd., Wockhardt Ltd.
North America was the largest region in the small volume parenteral market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small volume parenteral market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the small volume parenteral market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The small volume parenteral market consists of sales of epinephrine, insulin, heparin, morphine, and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Small Volume Parenteral Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses small volume parenteral market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for small volume parenteral ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small volume parenteral market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.